首页> 外文期刊>Obstetrics and Gynecology: Journal of the American College of Obstetricians and Gynecologists >Radiofrequency catheter ablation in drug refractory maternal supraventricular tachycardias in advanced pregnancy.
【24h】

Radiofrequency catheter ablation in drug refractory maternal supraventricular tachycardias in advanced pregnancy.

机译:射频导管消融治疗晚期孕妇难治性母亲室上性心动过速。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Treatment of maternal tachyarrhythmias in pregnancy is a major clinical issue. Pharmacological treatment raises important concerns regarding partial efficacy and side effects. Radiofrequency ablation of arrhythmogenic substrate has rarely been performed during pregnancy because of the fetal risks related to x-ray exposure and potential fetomaternal procedural complications. CASES: Three women affected by supraventricular tachycardias refractory to pharmacological therapy underwent successful radiofrequency catheter ablation at 29 to 30 weeks' pregnancy. All patients had cesarean delivery of newborns with normal Apgar scores. CONCLUSION: Radiofrequency catheter ablation is an effective treatment of drug refractory maternal supraventricular tachycardias in advanced pregnancy. Further studies are required to establish its long-term fetal safety.
机译:背景:孕妇孕期快速性心律失常的治疗是一个主要的临床问题。药物治疗引起对部分功效和副作用的重要关注。由于与X射线暴露有关的胎儿风险和潜在的母系母亲手术并发症,很少在妊娠期进行射频消融致心律失常的基质。案例:3例因药理学治疗难治的室上性心动过速患者在妊娠29至30周成功进行了射频导管消融术。所有患者均进行剖宫产,新生儿的Apgar评分正常。结论:射频消融术是晚期妊娠药物性难治性母亲室上性心动过速的有效治疗方法。需要进一步研究以建立其长期胎儿安全性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号